Miacalcic (Calcitonin Salmon)
Calcium-regulating hormone for bone disorders and hypercalcemia
Miacalcic contains calcitonin salmon, a synthetic version of calcitonin — a hormone naturally produced by the thyroid gland that plays a key role in calcium and bone metabolism. It is primarily used to treat Paget's disease of bone, hypercalcemia of malignancy, and to prevent acute bone loss following sudden immobilization. Miacalcic is administered by subcutaneous or intramuscular injection and is available only by prescription.
Quick Facts: Miacalcic
Key Takeaways
- Miacalcic contains calcitonin salmon, a synthetic hormone that inhibits bone resorption by osteoclasts and promotes renal calcium excretion.
- It is approved for short-term treatment of Paget's disease, hypercalcemia of malignancy, and prevention of acute bone loss due to sudden immobilization.
- The European Medicines Agency (EMA) restricted calcitonin use in 2012 due to a slightly increased cancer risk with long-term use; the nasal spray form was withdrawn.
- The most common side effects include nausea, flushing, and injection site reactions; a skin test is recommended before first use due to possible allergic reactions.
- Treatment duration should be limited — typically 3 months for most indications, with periodic reassessment of the need for continued therapy.
What Is Miacalcic and What Is It Used For?
Miacalcic (calcitonin salmon) belongs to a group of medicines known as calcitonin preparations. Calcitonin is a polypeptide hormone naturally produced by the parafollicular C-cells of the thyroid gland. It plays a crucial role in regulating calcium homeostasis and bone metabolism. The salmon-derived synthetic version used in Miacalcic is approximately 40–50 times more potent than human calcitonin, making it suitable for therapeutic use at lower doses.
The medicine works through multiple mechanisms. Primarily, calcitonin salmon binds to specific receptors on osteoclasts — the cells responsible for breaking down bone tissue. By inhibiting osteoclast activity, it reduces the rate of bone resorption, which in turn lowers the release of calcium from bones into the bloodstream. Additionally, it promotes the excretion of calcium, phosphate, and sodium through the kidneys, contributing to its overall calcium-lowering effect.
Miacalcic is approved for the following clinical indications:
Paget's Disease of Bone
Paget's disease is a chronic condition characterized by abnormal bone remodeling, leading to enlarged, misshapen, and weakened bones. Calcitonin salmon has been a cornerstone treatment for this condition, particularly in patients who cannot tolerate bisphosphonates. By suppressing the overactive osteoclasts that characterize Paget's disease, Miacalcic helps reduce bone turnover, alleviate bone pain, and prevent complications such as pathological fractures, hearing loss, and neurological compression. Treatment typically results in a significant reduction in serum alkaline phosphatase levels and urinary hydroxyproline excretion, both markers of excessive bone turnover.
Hypercalcemia of Malignancy
Hypercalcemia — abnormally high levels of calcium in the blood — is a common and potentially life-threatening complication of various cancers, including lung, breast, and blood cancers. Miacalcic provides rapid reduction of serum calcium levels, typically within 2–4 hours of administration, making it valuable for acute management. While its calcium-lowering effect may diminish after 48–72 hours (a phenomenon known as "escape"), it serves as an important bridge therapy while other treatments such as bisphosphonates take full effect.
Prevention of Acute Bone Loss
In patients who are suddenly immobilized, for example following osteoporotic vertebral fractures, rapid bone loss can occur due to the absence of mechanical loading on the skeleton. Miacalcic helps preserve bone mass during this critical period of immobilization. It may also provide analgesic effects in patients with acute painful vertebral crush fractures, potentially reducing the need for opioid analgesics and improving early mobilization.
In 2012, the European Medicines Agency (EMA) concluded a safety review and recommended restricting the use of calcitonin-containing medicines. The nasal spray formulation was withdrawn in the European Union because the benefits no longer outweighed the risks for osteoporosis treatment. The injectable form remains available for short-term use in Paget's disease, hypercalcemia of malignancy, and prevention of acute bone loss, where the therapeutic benefits clearly outweigh the identified risks.
What Should You Know Before Taking Miacalcic?
Before initiating treatment with Miacalcic, a thorough medical evaluation is essential. Your healthcare provider needs comprehensive information about your medical history, current medications, and any known allergies to ensure this medicine is safe and appropriate for you. Because calcitonin salmon is derived from salmon, patients with a known hypersensitivity to salmon or fish products may be at increased risk of allergic reactions.
Contraindications
Miacalcic must not be used in the following situations:
- Hypersensitivity: Known allergy to calcitonin salmon, salcatonin, or any of the excipients in the formulation. Because the active ingredient is derived from salmon calcitonin, patients with documented fish or salmon allergy should not receive this medication.
- Hypocalcemia: Patients with existing low blood calcium levels, as calcitonin further lowers serum calcium and could cause dangerous hypocalcemia, potentially leading to tetany, seizures, or cardiac arrhythmias.
Warnings and Precautions
Several important precautions should be observed during treatment with Miacalcic:
- Allergy skin testing: A skin test is recommended before the first administration, particularly in patients with a history of allergic conditions. The test involves injecting a small amount of diluted calcitonin solution intradermally and observing for local or systemic reactions for 15 minutes.
- Cancer risk: A meta-analysis of clinical trial data revealed a statistically significant increase in cancer risk associated with long-term calcitonin use. While the absolute risk increase is small, treatment duration should be limited. For most indications, treatment should not exceed 3 months unless clinical need is compelling.
- Hypocalcemia monitoring: Serum calcium levels should be monitored regularly during treatment. Patients should be advised about symptoms of low calcium, including tingling in fingers and toes, muscle cramps, and numbness around the mouth.
- Escape phenomenon: In some patients, the therapeutic effect of calcitonin may diminish over time due to receptor downregulation. This is particularly relevant in the treatment of hypercalcemia, where alternative therapies may need to be considered if the response diminishes.
- Renal impairment: While no specific dose adjustment is required, calcitonin is primarily cleared by the kidneys. Patients with severe renal impairment should be monitored more closely for adverse effects.
Pregnancy and Breastfeeding
Miacalcic is not recommended during pregnancy. Animal studies have demonstrated that calcitonin crosses the placenta and may be associated with reduced birth weight and delayed ossification in the developing fetus. There are no adequate and well-controlled studies in pregnant women. The medicine should only be used during pregnancy if the potential benefit clearly justifies the potential risk to the fetus.
Calcitonin is also not recommended during breastfeeding. It has been shown to inhibit lactation in animal studies, and it is not known whether calcitonin is excreted in human breast milk. Given the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Although rare, serious allergic reactions (including anaphylaxis) have been reported with calcitonin salmon. A skin test should be performed before the first administration. Emergency resuscitation equipment and medication should be available when administering the first dose. Signs of a serious allergic reaction include difficulty breathing, swelling of the face or throat, rapid heartbeat, and severe dizziness.
How Does Miacalcic Interact with Other Drugs?
Compared to many other medications, calcitonin salmon has a relatively limited drug interaction profile. However, certain interactions are clinically significant and require careful management. The primary concern relates to the effects of calcitonin on calcium homeostasis, which can influence the pharmacodynamics of other calcium-sensitive medications.
The mechanisms underlying these interactions relate primarily to calcitonin's ability to lower serum calcium and alter electrolyte balance. Since many medications depend on stable calcium levels for their therapeutic effect or are influenced by renal electrolyte handling, concurrent use with calcitonin requires awareness and sometimes dose adjustment.
Major Interactions
| Drug | Interaction | Clinical Significance | Management |
|---|---|---|---|
| Lithium | Calcitonin may reduce plasma lithium concentrations by increasing renal lithium excretion | May lead to subtherapeutic lithium levels and loss of mood stabilization | Monitor lithium levels closely; dose adjustment may be required |
| Cardiac Glycosides (Digoxin) | Calcitonin-induced changes in serum calcium may potentiate or alter the effects of cardiac glycosides | Hypocalcemia increases the risk of digitalis toxicity; altered calcium levels affect cardiac contractility | Monitor serum calcium and digoxin levels; watch for signs of digitalis toxicity |
Minor Interactions
| Drug | Interaction | Management |
|---|---|---|
| Bisphosphonates | Both drugs inhibit bone resorption; combined use may enhance calcium-lowering effects | Monitor calcium levels; this combination may be used therapeutically in severe hypercalcemia |
| Calcium supplements | May partially counteract the calcium-lowering effect of calcitonin | Timing of administration may need adjustment; discuss with prescriber |
| Vitamin D supplements | May partially counteract calcitonin's hypocalcemic effect by increasing intestinal calcium absorption | May require monitoring if co-administered for osteoporosis prevention |
It is essential to inform your healthcare provider about all prescription medications, over-the-counter drugs, herbal supplements, and vitamins you are taking before starting Miacalcic. This includes any medications you may have recently stopped taking, as some drugs have prolonged effects on calcium metabolism.
What Is the Correct Dosage of Miacalcic?
The dosage of Miacalcic varies according to the clinical indication, the severity of the condition, and the patient's individual response to treatment. It is administered by subcutaneous (under the skin) or intramuscular (into the muscle) injection. Subcutaneous injection is generally preferred for self-administration, while intramuscular injection may be used in clinical settings for larger volumes.
Adults
Paget's Disease of Bone
Recommended dose: 100 IU (1 ml) daily, administered by subcutaneous or intramuscular injection.
Duration: Typically 3 months; re-evaluate the need for continued treatment. Some patients may respond to 50 IU daily or 100 IU three times per week.
Monitoring: Serum alkaline phosphatase and urinary hydroxyproline should be measured to assess response. A reduction of 50% or more in alkaline phosphatase typically indicates an adequate response.
Hypercalcemia of Malignancy
Starting dose: 100 IU (1 ml) every 6–8 hours by subcutaneous or intramuscular injection.
Dose escalation: If response is inadequate after 1–2 days, the dose may be increased to a maximum of 400 IU (4 ml) every 6–8 hours.
Duration: Short-term use only (usually 2–3 days); typically used as bridge therapy until bisphosphonates or other treatments take full effect.
Prevention of Acute Bone Loss
Recommended dose: 100 IU (1 ml) daily or 50 IU (0.5 ml) twice daily by subcutaneous or intramuscular injection.
Duration: 2–4 weeks, or for the duration of immobilization.
Note: Adequate calcium (at least 600 mg daily) and vitamin D supplementation should be ensured during treatment.
Children
The safety and efficacy of Miacalcic in children and adolescents (under 18 years of age) have not been established. There are insufficient clinical data to support a dosage recommendation for pediatric patients. Miacalcic should not be used in children unless the potential benefit clearly outweighs the unknown risks, and only under the supervision of a specialist physician experienced in managing pediatric bone disorders.
Elderly
No specific dose adjustment is required in elderly patients based on age alone. However, elderly patients are more likely to have decreased renal function, which should be taken into account. As with all patients, the lowest effective dose should be used for the shortest duration necessary. Elderly patients may also be more susceptible to the gastrointestinal side effects (nausea and vomiting) associated with calcitonin treatment.
Missed Dose
If you miss a dose of Miacalcic, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed injection. If you frequently forget doses, discuss with your healthcare provider about setting reminders or adjusting your treatment schedule.
Overdose
In case of calcitonin overdose, symptoms may include nausea, vomiting, facial flushing, dizziness, and tingling sensations. Severe overdose may cause hypocalcemia with muscle cramps, tetany, and cardiac arrhythmias. Contact your local poison control center or emergency department immediately. Treatment is supportive, with intravenous calcium gluconate administered if significant hypocalcemia develops.
What Are the Side Effects of Miacalcic?
Like all medicines, Miacalcic can cause side effects, although not everybody gets them. The following side effects have been reported during clinical trials and post-marketing surveillance. The frequency classifications below follow the standard convention used by the European Medicines Agency and the World Health Organization.
It is important to note that many of these side effects, particularly nausea and flushing, are dose-dependent and often diminish in intensity and frequency with continued treatment. Administration of the injection at bedtime, with the patient lying down, may help reduce the impact of nausea and dizziness. Anti-nausea medication may be prescribed if gastrointestinal symptoms are troublesome.
Very Common
- Nausea, with or without vomiting (up to 30% of patients in some studies; usually transient and dose-related)
- Facial flushing, warmth, or redness of the face and hands (occurs shortly after injection; typically resolves within 30–60 minutes)
Common
- Dizziness or lightheadedness
- Headache
- Injection site reactions (pain, redness, swelling at the injection site)
- Diarrhea or abdominal discomfort
- Taste disturbance (metallic taste)
- Fatigue or general malaise
- Musculoskeletal pain (joint pain, bone pain)
Uncommon
- Skin rash, itching, or urticaria (hives)
- Increased urinary frequency (polyuria)
- Visual disturbances
- Edema (swelling of hands or feet)
- Hypertension (elevated blood pressure)
Rare
- Anaphylaxis or severe allergic reactions (may include bronchospasm, tongue or throat swelling, and shock)
- Antibody formation (development of neutralizing antibodies to calcitonin salmon, which may reduce therapeutic efficacy over time)
- Hypocalcemia with symptoms of tetany (muscle spasms, tingling, numbness)
- Tremor
A meta-analysis conducted by the EMA found a statistically significant, though small, increase in the incidence of malignancies associated with long-term calcitonin use (overall cancer risk: 4.1% with calcitonin vs. 2.9% with placebo). This finding led to the restriction of calcitonin use to short-term indications and withdrawal of the nasal spray formulation for osteoporosis. For the injectable form, the benefits in approved indications are considered to outweigh this risk when used for limited durations.
If you experience any side effects, including those not listed above, please consult your healthcare provider. You can also report side effects directly to your national pharmacovigilance authority (for example, the Yellow Card Scheme in the UK, MedWatch in the US, or the corresponding system in your country).
How Should You Store Miacalcic?
Proper storage of Miacalcic is essential to maintain the stability and efficacy of the medication. Calcitonin salmon is a peptide hormone that is sensitive to temperature, light, and physical agitation. Failure to store the medication correctly may result in degradation of the active ingredient, potentially reducing its therapeutic effectiveness or producing harmful breakdown products.
The following storage guidelines should be strictly observed:
- Temperature: Store in a refrigerator at 2–8°C (36–46°F). The medication should be kept within this temperature range at all times prior to use. Brief excursions to room temperature (up to 25°C) during transport are acceptable but should be minimized.
- Freezing: Do not freeze. Freezing can cause irreversible structural changes to the calcitonin molecule, rendering the medication ineffective. If the solution has been accidentally frozen, it must be discarded.
- Light protection: Keep the ampoules in the original outer carton to protect from light. Exposure to direct sunlight or strong artificial light can accelerate degradation of the peptide.
- After opening: Miacalcic ampoules are intended for single use. Once an ampoule is opened, any unused solution should be discarded immediately. Do not store opened ampoules for later use.
- Visual inspection: Before administration, visually inspect the solution. It should be clear and colorless. Do not use if the solution appears discolored, cloudy, or contains visible particles.
- Expiry date: Do not use Miacalcic after the expiry date printed on the packaging (month/year). The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist about how to properly dispose of medicines you no longer need. These measures help protect the environment.
If you are traveling with Miacalcic, use a medical cool bag or insulated container with ice packs to maintain the required temperature range. Inform airline staff if you are carrying injectable medication in your hand luggage, and carry a letter from your doctor confirming your need for the medication.
What Does Miacalcic Contain?
Understanding the composition of Miacalcic helps patients and healthcare providers identify potential allergens and incompatibilities. The formulation is designed to ensure stability of the peptide hormone while maintaining appropriate pH and osmolality for injectable administration.
Active Ingredient
The active substance in Miacalcic is calcitonin (salmon), also known as salcatonin. Each 1 ml ampoule contains 100 International Units (IU) of synthetic salmon calcitonin. This is a 32-amino acid polypeptide hormone produced by recombinant DNA technology or chemical synthesis. It is structurally identical to the calcitonin found in Atlantic salmon (Salmo salar) and differs from human calcitonin in 16 of its 32 amino acid positions, which accounts for its enhanced potency and longer duration of action.
Excipients (Inactive Ingredients)
The solution for injection contains the following excipients:
- Acetic acid, glacial: Used as a pH buffer to maintain the solution at the optimal pH for stability and compatibility with injectable administration.
- Sodium acetate trihydrate: Works in conjunction with acetic acid as part of the acetate buffer system to maintain the pH of the solution.
- Sodium chloride: Provides isotonicity, ensuring the solution has an osmolarity compatible with physiological fluids and minimizing pain and tissue irritation at the injection site.
- Water for injections: The solvent, which meets pharmacopoeial standards for sterility and pyrogen-free quality.
The solution is preservative-free, which is why each ampoule is designed for single use only. The absence of preservatives reduces the risk of preservative-related adverse reactions but means that any unused portion must be discarded after the ampoule is opened to prevent microbial contamination.
Frequently Asked Questions About Miacalcic
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA) (2013). "Assessment report for calcitonin-containing medicinal products." EMA Calcitonin Referral EMA safety review leading to restriction of calcitonin use. Evidence level: Regulatory assessment.
- Chesnut CH 3rd, et al. (2000). "A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the PROOF study." American Journal of Medicine. 109(4):267-276. Landmark randomized controlled trial on calcitonin efficacy. Evidence level: 1B.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines." WHO Essential Medicines WHO's list of essential medicines for global health priorities.
- Ralston SH, et al. (2019). "Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline." Journal of Bone and Mineral Research. 34(4):579-604. https://doi.org/10.1002/jbmr.3657 International clinical guideline for Paget's disease management. Evidence level: 1A.
- Hu MI, et al. (2014). "Calcitonin therapy in the treatment of hypercalcemia." Endocrine Practice. 20(5):484-492. Review of calcitonin's role in managing hypercalcemia of malignancy.
- FDA (2015). "Miacalcin (calcitonin-salmon) Injection Prescribing Information." FDA Label Official FDA-approved prescribing information for Miacalcin injection.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in endocrinology, bone metabolism, and clinical pharmacology
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic background and clinical experience. Our editorial team includes:
Endocrinology Specialists
Licensed physicians specializing in endocrinology and metabolic bone disease, with documented experience in calcium metabolism disorders and hormonal therapies.
Clinical Pharmacologists
Academic researchers and practitioners with expertise in drug safety, pharmacokinetics, and pharmaceutical regulatory affairs.
Clinicians
Practicing physicians with over 10 years of clinical experience managing patients with metabolic bone disorders, osteoporosis, and hypercalcemia.
Medical Review
Independent review panel that verifies all content against international medical guidelines and current research.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence
- Members of international endocrinology and bone metabolism societies
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer review before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in endocrinology, clinical pharmacology, and internal medicine.